Skip to main content

Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.

Ye P, Zhang M, Fan S, Zhang T, Fu H, Su X, Gavine PR, Liu Q, Yin X

Publication: PLoS One (2015) • Vol 10 • Page e0143207PMID: 26587992View on PubMed

Purpose

The purpose of this paper was to determine the number of biopsies necessary to compensate for gastric tumor heterogeneity in immunohistochemistry (IHC) staining for mesenchymal-epithelial transition factor (MET) , ataxia telangiectasia mutated (ATM) and human epithelial growth factor receptor2 (HER-2), as well as  and fluorescent in situ hybridization (FISH) analysis of MET, fibroblast growth factor receptor 2 (FGFR2) and HER-2 . 

Conclusion

Overall, 47% of cases had 3-4 positive biopsies, 25% had 5-6 positive biopsies, 20% had ≤2 positive biopsies, and 8% had ≥7 positive biopsies based on IHC and FISH staining of the 5 markers evaluated. Although, low heterogeneity (present in > 50% of cores) occurred for >50% of cases for each of the markers, medium heterogeneity and high heterogeneity were observed in 15%-35% and 0-11% of cases, respectively. The false negative rate ranged from 0.19% (ATM by IHC)-3.70% (FGFR2 by FISH) with 4 biopsies and from 0.00% (HER-2 status)-1.10% (MET FISH) with 6 biopsies. 

Studies (1)

Purpose

The purpose of this study was to determine the number of biopsies necessary to compensate for gastric tumor heterogeneity in MET, ATM and HER-2 IHC staining, as well as MET, FGFR2 and HER-2 FISH staining.  A total of 1-9 biopsies were obtained from each of 166 patients with gastric tumors over an 8 year period. A threshold of >50 tumor cells was used for inclusion. MET positivity by IHC was defined as a score of 3+ and positivity by FISH was an average copy number ≥5.  FGFR2 positivity was defined as ≥6 copies. ATM IHC was defined as positive if the score was >0. HER-2 was defined as positive based on an IHC score of 3+, or an IHC score of 2+ and gene amplification by FISH.  The case was determined to be MET IHC-, MET FISH-, FGFR2 FISH-, ATM IHC- and HER2-positive if positive staining was observed in any biopsy and negative only if all biopsies were negative.  Heterogeneity was defined based on positive staining, as described above, and was considered high if it occurred  in less than 25% of biopsies, medium if present in 25-50% of biopsies, and low if present in ≥50% of biopsies.

Summary of Findings

Overall, 20% had ≤2 positive biopsies, 47% of cases had 3-4 positive biopsies, 25% had 5-6 positive biopsies, and 8% had ≥7 positive biopsies. Of the 18 cases that were MET positive by IHC, 11 (61%) had low heterogeneity (present in >50% of biopsies), 6 (33%) had medium heterogeneity (present in 25-50% of biopsies) and 1 (5.5%) had high heterogeneity (present in <25% of biopsies). Similarly, for the 13 cases that were positive for MET amplification by FISH, 10 (77%) had low heterogeneity, 2 (15%) had low heterogeneity and 1 (8%) had high heterogeneity. MET IHC and MET FISH results were modestly correlated (κ=0.62, p<0.01). ATM heterogeneity was low in 36 of the 58 cases (62%) medium in 20 cases (35%), and high in 2 cases (3.8%). Of the 9 FGFR2 amplification positive cases by FISH, 5 (56%) had low heterogeneity, 3 (33%) had medium heterogeneity and 1 (11%) had high heterogeneity. Thirty-two cases were considered HER-2 positive, and 25 (78%) had low heterogeneity, and 7 (22%) had medium heterogeneity. The false negative rate for MET IHC, MET FISH, ATM IHC, FGFR2 FISH, and HER-2 (IHC and FISH) was 3.39%, 3.30%, 0.19%, 3.70% and 0.23%, respectively with 4 biopsies and 0.00%, 1.10%, 0.00%, 0.00% and 0.00%, respectively with 6 biopsies. 

  • Biospecimens

    TissueStomach
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNAFISH
    ProteinImmunohistochemistry
    MorphologyH-and-E microscopy
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsBiospecimen heterogeneity
    Intratumoral sampling (exact positions not specified)
    FISH SpecificTargeted nucleic acid
    FGFR2
    HER-2/CEP17
    MET
    Immunohistochemistry SpecificTargeted peptide/protein
    ATM
    HER-2
    MET